Learn about PERJETA®, a neoadjuvant and metastatic breast cancer treatment for patients with HER2-positive breast cancer. What does PERJETA treat? PERJETA ...
Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2-positive breast cancer, in combination with ...
This page contains brief information about pertuzumab and a collection of links to more information about the use of this drug, research results, and ...
Pertuzumab (Perjeta) side effects, what it’s used for, how it’s given, how it works, drug type, precautions and self care tips
Pertuzumab. On June 8, 2012, the U. S. Food and Drug Administration approved pertuzumab injection (PERJETA, Genentech, Inc.) for use in combination with trastuzumab ...
Easy to read patient leaflet for pertuzumab. Includes indications, proper use, special instructions, precautions, and possible side effects.
Read about the cancer treatment drug pertuzumab, also called Perjeta, including what it is, how it works and possible side effects.
Pertuzumab is a cancer medication that interferes with the growth and spread of cancer cells in the body. Pertuzumab is used together with other cancer medicines ...
Original Article from The New England Journal of Medicine — Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Brand name: Perjeta® Approved for use in combination with trastuzumab and doctaxel neoadjuvant treatment of HER2-positive breast cancer; Approved for use in ...